Amiloride
Amiloride, Midamor (amiloride) is a small molecule pharmaceutical. Amiloride was first approved as Midamor on 1982-01-01. It is used to treat ascites, cystic fibrosis, edema, heart failure, and hypertension amongst others in the USA. It is known to target sodium/hydrogen exchanger 5, transient receptor potential cation channel subfamily V member 2, gonadotropin-releasing hormone receptor, acid-sensing ion channel 3, short transient receptor potential channel 7, transient receptor potential cation channel subfamily A member 1, acid-sensing ion channel 2, polycystin-2-like protein 1, alpha-2A adrenergic receptor, short transient receptor potential channel 6, sodium/hydrogen exchanger 2, sodium/hydrogen exchanger 3, sodium/hydrogen exchanger 1, and acid-sensing ion channel 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Amiloride, Midamor (discontinued: Amiloride)
CombinationsAmiloride hydrochlorothiazide (discontinued: Amiloride hydrochlorothiazide, Hydro-ride, Moduretic)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Amiloride hydrochloride
Amiloride hydrochloride
+
Hydrochlorothiazide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MODURETIC 5-50 | Merck & Co | N-018201 DISCN | 1982-01-01 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| amiloride hydrochloride | ANDA | 2023-11-28 |
| amiloride hydrochloride and hydrochlorothiazide | ANDA | 2023-02-04 |
| amiloride hydrocloride | New Drug Application | 2021-12-11 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
68 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 3 | 1 | 7 | 7 | 10 | 28 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 1 | — | 2 | 2 | 5 |
| Essential hypertension | D000075222 | — | I10 | — | — | 2 | 1 | 1 | 4 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | — | — | 1 | 1 | 3 |
| Chronic renal insufficiency | D051436 | — | N18 | — | 1 | — | 2 | — | 3 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 1 | — | — | 1 | 1 | 3 |
| Proteinuria | D011507 | HP_0000093 | R80 | 1 | — | — | 1 | — | 2 |
| Diabetes insipidus | D003919 | — | E23.2 | — | — | — | 1 | 1 | 2 |
| Nephrogenic diabetes insipidus | D018500 | — | N25.1 | — | — | — | 1 | 1 | 2 |
| Albuminuria | D000419 | EFO_0004285 | R80.9 | — | 1 | — | 1 | — | 2 |
Show 5 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | HP_0001635 | I50 | 2 | — | 1 | — | — | 3 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | 2 | — | — | 2 |
| Coronary disease | D003327 | — | — | — | 2 | 2 | — | — | 2 |
| Coronary artery disease | D003324 | — | I25.1 | — | 2 | 2 | — | — | 2 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 2 | 2 | — | — | 2 |
| Sleep apnea syndromes | D012891 | HP_0010535 | G47.3 | — | — | 2 | — | — | 2 |
| Apnea | D001049 | HP_0002104 | R06.81 | — | — | 2 | — | — | 2 |
| Insulin resistance | D007333 | HP_0000855 | — | — | 1 | 1 | — | 1 | 2 |
| Syndrome | D013577 | — | — | 1 | 1 | 1 | — | — | 2 |
| Hypernatremia | D006955 | HP_0003228 | E87.0 | — | — | 1 | — | 1 | 2 |
Show 8 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fibrosis | D005355 | — | — | 5 | 1 | — | — | 1 | 7 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | 5 | 1 | — | — | 1 | 7 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 2 | — | — | — | 2 |
| Sclerosis | D012598 | — | — | — | 2 | — | — | — | 2 |
| Neuritis | D009443 | — | — | — | 2 | — | — | — | 2 |
| Optic neuritis | D009902 | EFO_0007405 | H46 | — | 2 | — | — | — | 2 |
| Hypocalcemia | D006996 | HP_0002901 | E83.51 | — | 1 | — | — | — | 1 |
| Hypoparathyroidism | D007011 | HP_0000829 | E20 | — | 1 | — | — | — | 1 |
| Hypercalciuria | D053565 | HP_0002150 | R82.994 | — | 1 | — | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | — | — | — | 1 |
Show 5 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mucociliary clearance | D009079 | — | — | 3 | — | — | — | — | 3 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | 1 | — | — | — | — | 1 |
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | 1 | — | — | — | — | 1 |
| Heartburn | D006356 | — | R12 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | — | — | — | — | — | 1 | 1 |
| Nephritis | D009393 | — | N05 | — | — | — | — | 1 | 1 |
| Angina pectoris | D000787 | EFO_0003913 | I20 | — | — | — | — | 1 | 1 |
| Microvascular angina | D017566 | — | — | — | — | — | — | 1 | 1 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | — | — | — | 1 | 1 |
| Hyperaldosteronism | D006929 | HP_0011736 | E26 | — | — | — | — | 1 | 1 |
| Adenoma | D000236 | — | — | — | — | — | — | 1 | 1 |
| Hyperplasia | D006965 | EFO_0000536 | — | — | — | — | — | 1 | 1 |
| Congenital adrenal hyperplasia | D000312 | — | E25.0 | — | — | — | — | 1 | 1 |
| Adrenogenital syndrome | D047808 | — | E25.9 | — | — | — | — | 1 | 1 |
Show 3 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Amiloride |
| INN | amiloride |
| Description | Amiloride is a member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid. It has a role as a sodium channel blocker and a diuretic. It is a member of pyrazines, an organochlorine compound, an aromatic amine and a member of guanidines. It is a conjugate base of an amiloride(1+). |
| Classification | Small molecule |
| Drug class | epithelial sodium channel (ENaC) inhibitors, amiloride derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N=C(N)NC(=O)c1nc(Cl)c(N)nc1N |
Identifiers
| PDB | — |
| CAS-ID | 2609-46-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL945 |
| ChEBI ID | 2639 |
| PubChem CID | 16231 |
| DrugBank | DB00594 |
| UNII ID | 7DZO8EB0Z3 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
PKD2L1
PKD2L1
SLC9A3
SLC9A3
Organism
Homo sapiens
Gene name
PKD2L1
Gene synonyms
PKD2L, PKDL, TRPP3
NCBI Gene ID
Protein name
polycystin-2-like protein 1
Protein synonyms
Polycystic kidney disease 2-like 1 protein, Polycystin-2 homolog, polycystin-2L1, Polycystin-L, Polycystin-L1, transient receptor potential cation channel, subfamily P, member 3
Uniprot ID
Mouse ortholog
Pkd2l1 (329064)
polycystin-2-like protein 1; polycystic kidney disease 2-like 1 protein (Q80ZH4)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Amiloride
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Amiloride
+
Hydrochlorothiazide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 17,499 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,446 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use